Table of Contents
Abstract
CommitteeMembership
Foreword
1Scope
2Introduction
3StandardPrecautions
4Terminology
5ScientificBasisofHemolysis,Icterus,and
Lipemia/TurbidityIndices
6UseofHemolysis,Icterus,and
Lipemia/TurbidityIndices
7DeterminationofHemolysis,Icterus,and
Lipemia/TurbidityIndices
8EstimationofHemolysis,Icterus,
Lipemia/TurbidityInterferenceEffects
9EstablishingHemolysis,Icterus,and
Lipemia/TurbidityAlertIndicesandGrayZones
10ReportingHemolysis,Icterus,and
Lipemia/TurbidityInterferenceClaimsbyManufacturers
inProductLabeling
11PotentialProcessOutcomesofInterferent
Measurements/Estimates
12SuggestedAnnotationTerminologyforResult
Reporting
13VerificationandQualityControlofHemolysis,
Icterus,andLipemia/TurbidityIndicesandAlert
IndicesintheClinicalLaboratory
References
AppendixA-PathofWorkflowforHemolysis,Icterus,
andLipemia/TurbidityMeasurementsinthe
ClinicalLaboratory
AppendixB-WorkedExampleofEstablishing
Hemolysis,Icterus,andLipemia/Turbidity
Indices
TheQualityManagementSystemApproach
RelatedCLSIReferenceMaterials Abstract
Specifies background information on mechanisms of hemolysis, icterus, lipemia/turbidity (HIL) interference; intended usefulness of HIL indices; establishment of HIL alert indices; availability of automated HIL detection systems; and interpretation, strengths, limitations, and verification of HIL indices in the clinical laboratory.
